[Current aspects of immunomodulatory therapy initiation for sepsis].
Klinik für Anästhesiologie und Intensivtherapie, Klinikum der Friedrich-Schiller-Universität, Jena.
W
W
Karzai
H J
HJ
Gramm
K
K
Reinhart
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007116:Immunization, Passive; D007375:Interleukin-1 / Q000627:therapeutic use; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors; D018805:Sepsis / Q000209:etiology / Q000628:therapy*; D013256:Steroids; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000276:Adjuvants, Immunologic; D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D007375:Interleukin-1; D010972:Platelet Activating Factor; D013256:Steroids; D014409:Tumor Necrosis Factor-alpha; D016179:Granulocyte Colony-Stimulating Factor